Protecting the future: how plant stem cells guard against genetic damage

Scientists at the John Innes Centre in Norwich, UK, have shown how plants can protect themselves against genetic damage caused by environmental stresses. The growing tips of plant roots and shoots have an in-built mechanism that, if it detects damage to the DNA, causes the cell to ‘commit suicide’ rather than pass on its defective DNA.

Plants have, at the very tips of their roots and shoots, small populations of stem cells, through which they are able to grow and produce new tissue throughout the plant’s life. These stem cells are the precursors to producing plant tissues and organs. This means that any defect that arises in the stem cell’s genetic code will be passed on and persist irreversibly throughout the life of the plant, which may last thousands of years.

It is therefore critical that there are safeguards that prevent stem cell defects becoming fixed, particularly as the stem cells exist at the growing tips of shoots and roots where they are especially exposed to potentially hazardous environments.

Nick Fulcher and Robert Sablowski, with funding from the Biotechnology and Biological Sciences Research Council (BBSRC), set out to discover what these safeguards could be. By using X-rays and chemicals they were able to induce damage to DNA, and found that stem cells were much more sensitive to DNA damage than other cells. The cells are able to detect the DNA damage, triggering the death of these cells, thus preventing the damaged genetic code becoming fixed in the rest of the plant tissues.

A similar system exists in animal cells, which has been very well investigated, as the failure of this system can lead to cancer. The discovery of a similar, although distinct system in plants is therefore of great interest in the field of plant development, as well as in the efforts of scientists to develop plants better able to cope with environmental stress.

Drought, high salinity and the accumulation of hazardous chemicals in the soil are side-effects of a changing climate, so knowledge of how plants cope with theses stresses is of fundamental importance to agricultural science’s response to climate change. This is one aim of the research carried out by the John Innes Centre, an institute of the BBSRC.

from http://www.jic.ac.uk/corporate/media-and-public/current-releases/sablowskiDNAdamage.htm

Reblog this post [with Zemanta]

No Barriers to Stem Cell Transplantation for Older Patients with Blood Cancers

Age no longer should be a barrier to stem cell transplantation for older patients with blood cancersAge alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That’s the conclusion of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 and over who were treated with the mini-transplant, a “kinder, gentler” form of allogeneic (donor cell) stem cell transplantation developed at Fred Hutchinson Cancer Research Center. The findings are published Nov. 2 in JAMA, The Journal of the American Medical Association.

“Age is no longer a barrier to allogeneic transplant,” said Mohamed Sorror, M.D., M.Sc., an assistant member of the Hutchinson Center’s Clinical Research Division and corresponding author of the paper.

Sorror and colleagues found that the five-year rates of overall and disease-progression-free survival among mini-transplant patients were 35 percent and 32 percent, respectively. Patients in three age groups – 60 to 64, 65 to 69 and 70 to 75 – had comparable survival rates, which suggested that age played a limited role in how patients tolerate the mini-transplant. Increased medical problems unrelated to cancer (comorbidities) and a higher degree of cancer aggressiveness were the two factors that affected survival among those older patients. For example, patients who had less-aggressive cancer and fewer comorbidities had a five-year survival rate of 69 percent, while patients with more aggressive cancer and a significant number of comorbidities had a survival rate of 23 percent, regardless of age.Although a long-term survival rate of one-third of patients may seem low, these patients all would have died of their diseases within a matter of months without a transplant. “The majority of patients were referred for a transplant after they had exhausted all forms of conventional therapy,” said Sorror, who works in the research group led by Rainer Storb, M.D., who developed the mini-transplant.

Continue reading

A new stem cells source: Amniocentesis

The first world bank storing stem cells taken from amniotic fluid is “made in Italy”: it’s a private hospital in Busto Arsizio, near Milan.
Women planning amniocentesis – removal of amniotic fluid from the uterus (test done during pregnancy) – can ask for the “conservation set”, which will be given to the gynaecologist.
3 millilitre of amniotic liquid are enough to find some particular kind of stem cells very close to embryonic stem cells and suitable for in vitro breeding.
Then the test tube will be sent to the company which will store it for 20 years at -320°F. Some “experts” says that those cells are not enough for getting necessary cells for a cure.

Patient’s Own Stem Cells Might Treat Heart Attack

Emory University Seal
Image via Wikipedia

Treating a heart attack with the patients’ own bone marrow stem cells boosts blood flow within the heart and may help reduce long-term complications, a new U.S. study finds.
The study included 31 patients who underwent angioplasty and stent placement after a heart attack. Within one week of the attacks, 16 of the patients received infusions of their own bone marrow cells into the coronary artery in which a blockage had caused the event.

The 16 patients received different amounts of bone marrow stem cells — 5 million, 10 million and 15 million cells. The 15 patients in the control group received standard medication only. All the patients were followed for up to five years.
After three to six months, patients who received higher doses of bone marrow stem cells showed greater improvement in blood flow within the heart than patients who received lower doses and those in the control group, the researchers said.

Continue reading

Experimental drug shows promise against brain, prostate cancers

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

The drug’s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer’s growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The glioblastoma study appears in the January issue of Clinical Cancer Research. The prostate cancer study is available online in the International Journal of Cancer.

Continue reading

Incoming search terms:

latest stem cell research and cancer.